CN101120970A - Phenolic extract of duchesnea indica focke, preparation method and application thereof - Google Patents
Phenolic extract of duchesnea indica focke, preparation method and application thereof Download PDFInfo
- Publication number
- CN101120970A CN101120970A CNA2007100630006A CN200710063000A CN101120970A CN 101120970 A CN101120970 A CN 101120970A CN A2007100630006 A CNA2007100630006 A CN A2007100630006A CN 200710063000 A CN200710063000 A CN 200710063000A CN 101120970 A CN101120970 A CN 101120970A
- Authority
- CN
- China
- Prior art keywords
- extract
- herba duchesneae
- duchesneae indicae
- ethanol
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 239000000284 extract Substances 0.000 title claims description 37
- 244000084767 Potentilla indica Species 0.000 title abstract 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 57
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 19
- 238000000605 extraction Methods 0.000 claims abstract description 13
- 238000010828 elution Methods 0.000 claims abstract description 11
- 239000007788 liquid Substances 0.000 claims abstract description 11
- 239000011347 resin Substances 0.000 claims abstract description 11
- 229920005989 resin Polymers 0.000 claims abstract description 11
- 238000002791 soaking Methods 0.000 claims abstract description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 6
- 201000011216 nasopharynx carcinoma Diseases 0.000 claims abstract description 5
- 206010008342 Cervix carcinoma Diseases 0.000 claims abstract description 4
- 206010014759 Endometrial neoplasm Diseases 0.000 claims abstract description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims abstract description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims abstract description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims abstract description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims abstract description 4
- 201000010881 cervical cancer Diseases 0.000 claims abstract description 4
- 206010017758 gastric cancer Diseases 0.000 claims abstract description 4
- 201000011549 stomach cancer Diseases 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 11
- 230000000274 adsorptive effect Effects 0.000 claims description 10
- 239000000243 solution Substances 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 235000002639 sodium chloride Nutrition 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 5
- 235000001014 amino acid Nutrition 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 claims description 4
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 201000003914 endometrial carcinoma Diseases 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 2
- 230000036039 immunity Effects 0.000 claims description 2
- 239000000049 pigment Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 235000018102 proteins Nutrition 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 239000006286 aqueous extract Substances 0.000 claims 1
- 238000007796 conventional method Methods 0.000 claims 1
- 230000006837 decompression Effects 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 abstract description 11
- 230000006870 function Effects 0.000 abstract description 4
- 201000011510 cancer Diseases 0.000 abstract description 2
- 244000025254 Cannabis sativa Species 0.000 abstract 1
- 206010014733 Endometrial cancer Diseases 0.000 abstract 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 201000007270 liver cancer Diseases 0.000 abstract 1
- 208000014018 liver neoplasm Diseases 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 208000025848 malignant tumor of nasopharynx Diseases 0.000 abstract 1
- 239000011259 mixed solution Substances 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 8
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 230000036737 immune function Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 3
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 3
- 235000012734 epicatechin Nutrition 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 239000002023 wood Substances 0.000 description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000003228 hemolysin Substances 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000000527 lymphocytic effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000009849 Female Genital Neoplasms Diseases 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001529246 Platymiscium Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- -1 transfusion etc.) Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses an Indian strawberry phenol extraction extracted from an Indian strawberry whole grass, which also relates to the preparation method of the extraction and the function of the extraction. The preparation method of the Indian strawberry phenol extraction is as following, which comprises soaking and extraction of the Indian strawberry by water, ethanol, or a mixed solution with water and ethanol in a certain ratio; vacuum concentration of the Indian strawberry extraction liquid; then the ethanol is removed from the extraction liquid and passed through a malodorous resin column; the liquid is eluted by the ethanol after elution of the non affection component with the water; the ethanol elution liquid and vacuum concentration are collected, therefore the Indian strawberry phenol extraction is obtained. The Indian strawberry phenol extraction of the present invention possesses functions of prohibiting the generation and growth of various kinds of tumor cells. Therefore the present invention is applicable for treatment of a plurality of cancer diseases comprising the lung cancer, the liver cancer, the nasopharynx cancer, the gastric cancer, the cervical cancer, the endometrium cancer and the ovarian cancer, etc. In addition, the Indian strawberry phenol extraction in the present invention has active function of improving the immune ability in the organism.
Description
Technical field
The present invention relates to a kind of Chinese medicine effective component extracts, relate in particular to a kind of phenol extract that obtains that from the plant Herba Duchesneae Indicae, extracts, the invention still further relates to the purposes of this this preparation method of extract and this extract, belong to the field of Chinese medicines.
Background technology
Herba Duchesneae Indicae [Drchesnea indica (Andr) Focke] is a Rosaceae Herba Duchesneae Indicae platymiscium, call three wind, the certain kind of berries, Herba Duchesneae Indicae, five-fingered jack, wild Fructus Myricae rubrae etc., be medical herbs commonly used among the people.Herba Duchesneae Indicae has heat-clearing and toxic substances removing, detumescence dissipating blood stasis, the effect of astringing to arrest bleeding, removing heat from blood with all herbal medicine.Existing bibliographical information Herba Duchesneae Indicae has notable antitumor activity, but what reported all is that the water of Herba Duchesneae Indicae is carried or the crude extract of alcohol extraction, up to now, does not obtain the antitumor component of Herba Duchesneae Indicae as yet.
Summary of the invention
Technical problem to be solved by this invention is to overcome the deficiencies in the prior art, and the antitumor component of a kind of Herba Duchesneae Indicae is provided, promptly Herba Duchesneae Indicae phenol extract (Drchesnea polyphenolic extract, DPE).
Technical problem to be solved by this invention is achieved through the following technical solutions:
A kind of method for preparing Herba Duchesneae Indicae phenol extract comprises:
(1) mixed liquor formed with arbitrary proportion of water, 50-80% ethanol or ethanol and water serves as to extract solvent soaking to extract Herba Duchesneae Indicae (extracting solvent did not have Herba Duchesneae Indicae to get final product), filter the Herba Duchesneae Indicae extracting solution;
(2) will pass through macroporous adsorptive resins behind the Herba Duchesneae Indicae extracting solution concentrating under reduced pressure removal ethanol, behind elder generation's water flush away non-active ingredients, reuse 50-95% ethanol (90-95% ethanol more preferably) eluting macroporous adsorptive resins, collect ethanol elution, be evaporated to dried Herba Duchesneae Indicae phenol extract (DPE).
In the above-mentioned preparation method, preferred, the mixed liquor that water, 50-80% ethanol or ethanol and water are formed with arbitrary proportion in the step (1) serves as to extract solvent soaking to extract Herba Duchesneae Indicae 3 times, extracts 1 hour at every turn; Be to extract solvent soaking to extract Herba Duchesneae Indicae 3 times more preferably, extracted 1 hour at every turn with 80 ℃ of hot water.
Non-active ingredients described in the step (2) is sugar, organic salt, aminoacid, protein, pigment etc.;
Macroporous adsorptive resins is preferably and uses AB-8, D3520, DM130, D8, D101 or D201 macroporous adsorptive resins in the step (2).
Herba Duchesneae Indicae phenol extract of the present invention has propagation and the growth effect that suppresses kinds of tumor cells, can be used for multiple treatment for cancer, comprises pulmonary carcinoma, hepatocarcinoma, nasopharyngeal carcinoma, gastric cancer, cervical cancer, carcinoma of endometrium, ovarian cancer etc.; In addition, Herba Duchesneae Indicae phenol extract of the present invention can improve cell and humoral immune function.Therefore, Herba Duchesneae Indicae phenol extract of the present invention can be used for being prepared into the medicine of antitumor or raising body immunity.
After Herba Duchesneae Indicae phenol extract extract of the present invention can add various adjuvants and pharmaceutically acceptable excipient or carrier required when preparing different dosage form, method of Chinese medicinal with routine is prepared into any suitable clinical preparation, for example can be injection (powder pin, freeze-dried powder, liquid drugs injection, transfusion etc.), tablet, oral liquid, granule, capsule, soft capsule or drop pill etc.; Wherein, described adjuvant can be antioxygen chelating agent, filler, framework material etc.;
Described pharmaceutically acceptable carrier is one or more in xylitol, mannitol, lactose, fructose, glucosan, glucose, polyvinylpyrrolidone, low molecular dextran, sodium chloride, calcium gluconate or the calcium phosphate.
In order further to set forth the present invention, provide a series of embodiment below.These embodiment are illustrative fully, and they only are used for the present invention is specifically described, and not should be understood to limitation of the present invention.
The specific embodiment
Embodiment 1
Get Herba Duchesneae Indicae herb 200g, add 80 ℃ of hot water 3L, soak and extract 3 times, each 1 hour.Remove by filter medicinal residues, merge extractive liquid, slowly passes through AB-8 type macroporous adsorptive resins with extracting solution, behind non-active ingredients such as 10L washing desaccharide, organic salt, aminoacid, again with 6L 90% ethanol elution, collect ethanol elution, be evaporated to dried Herba Duchesneae Indicae phenol extract 11g.With spectrophotography (Scalbert A, Monties B, Jannin, G.Tanins in wood:comparison of different estimation methods.Journal of Agricultural andFood Chemistry 1989,37:1324-1329.) record, contain the phenol total amount in this extract and count 46.1% with epicatechin.
Embodiment 2
Get Herba Duchesneae Indicae herb 150g, add entry 2.5L, make and soaked powder, soak and extract 3 times, each 1 hour.Remove by filter medicinal residues, merge extractive liquid,, extracting solution is slowly passed through AB-8 type macroporous adsorptive resins, behind non-active ingredients such as 10L0.1% aqueous hydrochloric acid solution flush away sugar, organic salt, aminoacid, again with 6L 95% ethanol elution, collect ethanol elution, be evaporated to dried Herba Duchesneae Indicae phenol extract 9.6g.With spectrophotography (Scalbert A, Monties B, Jannin, G.Tanins in wood:comparison of different estimation methods.Journal of Agricultural and Food Chemistry 1989,37:1324-1329.) record, contain the phenol total amount in this extract and count 41.9% with epicatechin.
Embodiment 3
Get Herba Duchesneae Indicae herb 130g, add 80% ethanol 2L and soak extraction 3 times, each 1 hour.Remove by filter medicinal residues, merge extractive liquid,, after the extracting solution concentrating under reduced pressure removed ethanol, add the dilution of 5L water, filtrate is by D3520 type macroporous adsorptive resins, earlier with non-active ingredients such as 10L washing desaccharide, organic salt, aminoacid, again with 6L 90% ethanol elution, collect ethanol elution, be evaporated to dried Herba Duchesneae Indicae phenol extract 5.2g.With spectrophotography (Scalbert A, Monties B, Jannin, G.Tanins in wood:comparison of different estimationmethods.Journal of Agricultural and Food Chemistry 1989,37:1324-1329.) record, contain the phenol total amount in this extract and count 40.2% with epicatechin.
Test example 1 Herba Duchesneae Indicae phenol extract is to the inhibitory action of growth of human tumor cells
The take the logarithm tumor cell (available from China Concord Medical Science University basis institute cell centre) of trophophase is inoculated in 96 orifice plates with 5000/hole, in 37 ℃ of 5%CO
2Cultivate after 10-12 hour under the condition, the administration group adds DPE (embodiment of the invention 1,2 or 3 is prepared), making its final concentration is 20-240 μ g/mL, the blank group is 0.08% dimethyl sulfoxide, positive controls is the cisplatin of 20nmol/L, adopt the MTT colorimetry, measure the absorbance A value in wavelength 570nm/650nm place.Calculate the suppression ratio of medicine according to the A value to growth of tumour cell.
The growth inhibition ratio of tumor cell=(the A value of the A value/negative control group of 1-experimental group) * 100%
Result of the test shows that DPE has inhibition proliferation function (table 1) to kinds of tumor cells, especially pulmonary carcinoma, nasopharyngeal carcinoma and hepatoma carcinoma cell is had very strong inhibitory action, and the gynecological tumor cell is also had good inhibitory effect.
Table 1. Herba Duchesneae Indicae phenol extract is to the inhibited proliferation of tumor cell
Cell strain | Suppression ratio (IC 50,μg/m1) | |
Hela | Cervical cancer | 89.83±8.02 |
SKOV-3 | Ovarian cancer | 80.68±3.41 |
HEC-1B | Carcinoma of endometrium | 223.8±22.61 |
BGC-823 | Gastric cancer | 112.63±0.07 |
NCI-H460 | Pulmonary carcinoma | 143.87±25.01 |
L78 | Pulmonary carcinoma | 22.50±4.05 |
CNE | Nasopharyngeal carcinoma | 63.24±3.01 |
Bel-7402 | Hepatocarcinoma | 29.00±3.01 |
Hep G2 | Hepatocarcinoma | 63.18±2.14 |
Test example 2 Herba Duchesneae Indicae phenol extracts are to the inhibitory action of mice transplanted tumor U14
Get well-grown ascites cells (available from institute of Materia Medica,Chinese Academy of Medical Sciences), washing back makes with an amount of physiological saline solution that to contain cell number be 2.5 * 10
7The tumor cell suspension of individual/mL.0.2mL (contains oncocyte 5 * 10 respectively at right this tumor cell suspension of axillary fossa subcutaneous vaccination of mice (available from Chinese Academy of Medical Sciences's animal center)
6Individual).Inoculation is divided into 5 groups at random with mice with tumor next day, every group 10, wherein 3 groups are the administration group, and oral administration gavage gives DPE (embodiment of the invention 1,2 or 3 is prepared) with 3 various dose (0.25 respectively, 0.5 and 1g/kg), model group is that oral administration gavage gives the equal-volume distilled water.Administration group and model group all gavage 20 days continuously.Positive controls is intraperitoneal injection of cyclophosphamide (CTX) 60mg/kg, only gives once next day behind the inoculation oncocyte.Each treated animal is all conventional raises, drinking-water, and food is not limit.Mice all took off cervical vertebra in the time of 21 days puts to death, and strips subcutaneous solid tumor tumor piece, weighs, and calculates tumor control rate (%) by following formula.
Tumor control rate (%)=(the average tumor of the average tumor weight-experimental group of model group is heavy)/average tumor of model group heavy * 100%.
Result of the test (table 2) shows that the DPE of low dosage (0.25g/kg) has facilitation to the growth of mouse carcinoma of uterine cervix U14; And the DPE of high dose (0.5g/kg and 1g/kg) can obviously suppress the growth of U14, and tumour inhibiting rate is respectively 27% and 63%; Each dosage group of DPE there is no tangible toxic reaction, and mice all survived when treatment finished.
The effect of table 2.DPE anti-tumor in vivo (mean value SD, n=10)
The experiment grouping | Dosage (g/kg) | Tumor heavy (g) |
Contrast | - | 2.420±0.839 |
CTX | 0.06 | 0.652±0.756 |
DPE | 0.25 | 2.584±0.718 |
DPE | 0.5 | 1.150±0.590 ** |
DPE | 1 | 0.777±0.552 ** |
*, P<0.01 is compared with matched group
The test of test example 3 Herba Duchesneae Indicae phenol extract immunologic functions
1. pair cell Immune Effects-T lymphocyte transformation test
In test example 2, after the execution of 20 days U14 tumor-bearing mice of successive administration, under aseptic, get spleen immediately, grind with cold aseptic PBS flushing back, the splenocyte after the grinding makes 5 * 10 with the RPMI-1640 that contains 10% hyclone after the PBS washing
6The cell suspension of/mL.Add this cell suspension in 96 orifice plates, 100 μ L/ holes.And adding ConA 10 μ L (final concentration 2.5 μ g/mL).Cultivate after 60 hours, every hole adds MTT 20 μ L (final concentration 0.5mg/mL), continues to cultivate after 4 hours, adds three liquid, 100 μ L[and contains SDS 10% (w/v), isobutanol 5% (v/v) and HCl 0.01mol/L (v/v)], 37 ℃ are spent the night.Microplate reader 570nm place surveys absorption value A.
2. to the influence-hemolysin spectrophotography of humoral immune function
Select Kunming female mice (available from Chinese Academy of Medical Sciences's animal center) for use, after the inoculation of U14 oncocyte, animal grouping and route of administration, method, dosage and time are all identical in the example 2 with test, and the 5%SRBC to mouse peritoneal injection 0.4mL on the 16th makes animal sensitization in the inoculation back.Put to death animal and get spleen in drug withdrawal on the 21st.Spleen channel is ground, after the washing, make with cold PBS and to contain 2 * 10
10The cell suspension of/L.With this splenocyte suspension 1mL and 0.2%SRBC 1mL and 1: 10 abundant mixing of dilution complement 1mL, behind 37 ℃ of water-bath 60min, the centrifugal 5min of 3000rpm.Get supernatant and survey absorption value A in the 413nm place.
Above T lymphocyte transformation experiment and hemolysin spectrophotometric experimental result (table 3) show that compare with normal mouse, the cell and the humoral immune function of tumor-bearing mice all obviously weaken.Herba Duchesneae Indicae phenol extract 1g/kg can obviously promote the lymphocytic propagation of T of tumor-bearing mice; But the DPE of low dosage (0.25g/kg) obviously suppresses lymphocytic propagation.The DPE of various dose all can make the humoral immune function of tumor-bearing mice strengthen, and the antibody amount that shows as dose dependent increases.
The influence that table 3DPE discharges T lymphopoiesis and bone-marrow-derived lymphocyte antibody (mean value SD, n=10)
Group | Dosage (g/kg) | T lymphopoiesis (A 570value) | Antibody discharges (A 413 value) |
Normal | - | 0.449±0.144 | 0367±0.077 |
Model | - | 0.408±0.098 | 0.083±0.109## |
CTX | 0.06 | 0.322±0.046 * | 0.105±0.06 |
DPE | 0.25 | 0.270±0.072 ** | 0.153±0.119 |
DPE | 0.5 | 0.385±0.096 | 0.464±0.385 ** |
DPE | 1 | 0.588±0.112 ** | 0.512±0.337 ** |
##, P<0.01 is compared with normal group
*, P<0.05,
*, P<0.01 is compared with model group
Claims (10)
1. method for preparing Herba Duchesneae Indicae phenol extract comprises:
(1) mixed liquor formed with arbitrary proportion of water, 50-80% ethanol or ethanol and water serves as to extract solvent soaking to extract Herba Duchesneae Indicae, filters to remove medicinal residues and get the Herba Duchesneae Indicae extracting solution;
(2) the Herba Duchesneae Indicae extracting solution behind Herba Duchesneae Indicae aqueous extract or the decompression removal ethanol is passed through macroporous adsorptive resins, behind elder generation's water or the 0.1% hydrochloric acid flush away non-active ingredients,, collect ethanol elution again with the 50-95% ethanol elution, be evaporated to dried, Herba Duchesneae Indicae phenol extract.
2. according to the method for claim 1, it is characterized in that: the mixed liquor that water, 50-80% ethanol or ethanol and water are formed with arbitrary proportion in the step (1) serves as when extracting solvent soaking extraction Herba Duchesneae Indicae, to extract 3 times, extracts 1 hour at every turn.
3. according to the method for claim 2, it is characterized in that: step (1) is middle to be to extract solvent soaking to extract Herba Duchesneae Indicae with 80 ℃ of hot water.
4. according to the method for claim 1, it is characterized in that: the non-active ingredients described in the step (2) comprises sugar, organic salt, aminoacid, protein or pigment.
5. according to the method for claim 1, it is characterized in that: the macroporous adsorptive resins described in the step (2) is selected from AB-8, D3520, DM130, D8, D101 or D201 macroporous adsorptive resins.
6. Herba Duchesneae Indicae phenol extract is characterized in that: the product that is prepared by any one method of claim 1-5.
7. according to the Herba Duchesneae Indicae phenol extract of claim 6, it is characterized in that: be prepared into tablet, pill, granule, injection or oral liquid according to conventional method of Chinese medicinal.
8. the purposes of the Herba Duchesneae Indicae phenol extract of claim 6 in preparation medicine for treating tumor thing.
9. according to the purposes of claim 8, it is characterized in that: described tumor comprises pulmonary carcinoma, hepatocarcinoma, nasopharyngeal carcinoma, gastric cancer, cervical cancer, carcinoma of endometrium or ovarian cancer.
10. the purposes of the Herba Duchesneae Indicae phenol extract of claim 5 in preparation enhancing human body immunity power medicine.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200710063000A CN100586450C (en) | 2007-01-24 | 2007-01-24 | Phenolic extract of duchesnea indica focke, preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200710063000A CN100586450C (en) | 2007-01-24 | 2007-01-24 | Phenolic extract of duchesnea indica focke, preparation method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101120970A true CN101120970A (en) | 2008-02-13 |
CN100586450C CN100586450C (en) | 2010-02-03 |
Family
ID=39083608
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200710063000A Expired - Fee Related CN100586450C (en) | 2007-01-24 | 2007-01-24 | Phenolic extract of duchesnea indica focke, preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100586450C (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101701107A (en) * | 2009-10-29 | 2010-05-05 | 西北工业大学 | Preparation method of mock-strawberry fruit haematochrome |
CN101486771B (en) * | 2009-02-27 | 2011-08-24 | 中国药科大学 | Duchesnea polysaccharide, as well as preparation and use thereof |
CN103263455A (en) * | 2013-03-20 | 2013-08-28 | 中国医学科学院药用植物研究所 | Preparation and application of medicine with neuroprotective effect |
CN103768185A (en) * | 2012-10-25 | 2014-05-07 | 奇复康药物研发(苏州)有限公司 | Extraction method for Indian strawberry flavone |
CN112500468A (en) * | 2020-12-14 | 2021-03-16 | 上海交通大学 | Bioactive peptide RLAFIAHPKLG, and preparation method and application thereof |
CN116832088A (en) * | 2023-06-20 | 2023-10-03 | 重庆派佰乐生物科技有限公司 | Application of Indian mockstrawberry herb extract in preparation of constipation relieving medicine |
-
2007
- 2007-01-24 CN CN200710063000A patent/CN100586450C/en not_active Expired - Fee Related
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101486771B (en) * | 2009-02-27 | 2011-08-24 | 中国药科大学 | Duchesnea polysaccharide, as well as preparation and use thereof |
CN101701107A (en) * | 2009-10-29 | 2010-05-05 | 西北工业大学 | Preparation method of mock-strawberry fruit haematochrome |
CN103768185A (en) * | 2012-10-25 | 2014-05-07 | 奇复康药物研发(苏州)有限公司 | Extraction method for Indian strawberry flavone |
CN103263455A (en) * | 2013-03-20 | 2013-08-28 | 中国医学科学院药用植物研究所 | Preparation and application of medicine with neuroprotective effect |
CN103263455B (en) * | 2013-03-20 | 2018-04-06 | 中国医学科学院药用植物研究所 | A kind of preparation and application of the medicine with neuroprotection |
CN112500468A (en) * | 2020-12-14 | 2021-03-16 | 上海交通大学 | Bioactive peptide RLAFIAHPKLG, and preparation method and application thereof |
CN112500468B (en) * | 2020-12-14 | 2022-07-15 | 上海交通大学 | Bioactive peptide RLAFIAHPKLG, and preparation method and application thereof |
CN116832088A (en) * | 2023-06-20 | 2023-10-03 | 重庆派佰乐生物科技有限公司 | Application of Indian mockstrawberry herb extract in preparation of constipation relieving medicine |
Also Published As
Publication number | Publication date |
---|---|
CN100586450C (en) | 2010-02-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100586450C (en) | Phenolic extract of duchesnea indica focke, preparation method and application thereof | |
EP1945034B1 (en) | Herbal powder extracts and methods of preparing and using the same | |
CN103768534A (en) | Traditional Chinese medicinal composition with anti-tumor activity | |
CN102078569B (en) | Traditional Chinese medicine preparation for treating liver cancer and preparation method thereof | |
CN108210547B (en) | Preparation method of phyllanthus emblica leaf extract, preparation and anti-artemisia application thereof | |
CN101850032A (en) | Anti-tumor traditional Chinese medicine composition and preparation method and application thereof | |
CN101411779B (en) | Chinese medicine effective component composition for treating liver cancer and method for preparing the same | |
CN108348566A (en) | For treating liver and maintaining composition, method and the pharmaceutical composition of liver health | |
CN102319379A (en) | Formula for treating and preventing cancerous tumors and preparation and production process of Chinese caterpillar fungus tumor rehabilitation oral liquid | |
CN106109917A (en) | A kind of external treatment solution treating thyroid tumor | |
CN101357212B (en) | Compound cantharis injection and preparation method thereof | |
CN105477465A (en) | Chinese herb preparation with liver protection function and preparing technology of Chinese herb preparation | |
CN101007047B (en) | An antitumor medicine composition and its preparation method | |
CN101040899B (en) | Antineoplastic Chinese traditional compound and the preparation and the method for producing the same | |
CN101164558A (en) | Clot-dispersing pain-relieving medicinal composition and preparation method and application thereof | |
CN104491474A (en) | Traditional Chinese medicine composition for reducing blood glucose in assisted mode and preparation method thereof | |
CN1264547C (en) | Preparation of Chinese traditional medicine for treating coronary heart disease and angina as well as preparation method | |
CN103169844A (en) | Traditional Chinese medicine composition having anti-lung cancer and anti-liver cancer effects | |
CN103181992A (en) | Nightshade processing method | |
CN114129692B (en) | Traditional Chinese medicine composition for treating furunculosis and preparation method and application thereof | |
CN106620282A (en) | Herba dendrobii nobilis and American ginseng capsules and preparation method thereof | |
CN101708308B (en) | Anti-tumor medicinal composition without stimulation to gastrointestinal mucosae | |
CN106334018B (en) | Traditional Chinese medicine composition for treating hepatocellular carcinoma and application thereof | |
CN105287865A (en) | Medicinal composition for treating malignant tumor | |
CN104825784A (en) | Traditional Chinese medicine composition with anti-gastric cancer activity and preparation method and application of traditional Chinese medicine composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100203 Termination date: 20120124 |